Zoetis Inc.

Valuation Analysis

About the Company

Zoetis Inc. en bref

Zoetis Inc. (ZTS) is currently trading at 68,59 € with a market capitalization of 28,8 Md €. The trailing P/E ratio stands at 12.9x, with a forward P/E of 10.6x. The 52-week range spans from 63,10 € to 141,03 €; the current price is 51.4% below the yearly high. Year-over-year revenue growth stands at +2.9%. The net profit margin stands at 28.04%.

💰 Dividende

Zoetis Inc. pays an annual dividend of 1,85 € per share, representing a yield of 2.69%. The payout ratio stands at 33.28%.

📊 Avis des analystes

17 analystes évaluent Zoetis Inc. (ZTS) au consensus : Acheter. L'objectif de cours moyen est de 108,61 €, soit un potentiel de +58.35% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 78,46 € à 139,48 €.

Zoetis Inc. : la thèse d'investissement en détail

Zoetis Inc. (ZTS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 71.84%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 67.75% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 28.04%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Revenue growth has slowed to just 2.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. The debt-to-equity ratio of 286.24% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

The EV/EBITDA multiple of 9.96x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 10.6x is meaningfully below the trailing 12.9x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 58.35% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Zoetis Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.